Keros reports elritercept Phase 2 data: 134.1 wk median TI in MDS; spleen reductions in MF

Keros Therapeutics, Inc.

55.2% (48/87) of mITT patients achieved overall erythroid response; median TI duration 134.1 weeks in lower-risk MDS.
31.4% (16/51) of high-transfusion-burden MDS patients achieved TI >=8 weeks; 50% of those had TI >=24 weeks.
In MF, 63.4% (26/41) of transfusion-dependent patients had reduced RBC burden; 24.4% achieved TI.
40% (8/20) of MF patients with baseline spleen >=450 cm³ had spleen volume reduction at week 24; 3 had >=35% reduction.
Elritercept generally well-tolerated; Phase 3 RENEW trial in MDS expected to begin enrollment soon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.